Proteomic biomarkers in diabetic nephropathy-Reality or future promise?

Nephrology Dialysis Transplantation

Volumn 25, Issue 9, 2010, Pages 2843-2845

  Mischak, Harald ^a,b   Rossing, Peter ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Mosaiques Diagnostics GmbH   (Germany)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

diabetic nephropathy; prognosis; proteomics; urine

Indexed keywords

BIOLOGICAL MARKER; CANDESARTAN; COLLAGEN; OLMESARTAN; PLASMA PROTEIN; RAMIPRIL; TELMISARTAN;

CAPILLARY ELECTROPHORESIS; DIABETIC NEPHROPATHY; HIGH RISK PATIENT; HUMAN; MASS SPECTROMETRY; MICROALBUMINURIA; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; TREATMENT RESPONSE; TWO DIMENSIONAL ELECTROPHORESIS; URINALYSIS;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; PROTEINURIA; PROTEOME;

EID: 77956125132     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq363     Document Type: Note

References (21)

1. Ameur RB, Molina L, Bolvin C et al. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 2866-2875
2. Fliser D, Novak J, Thongboonkerd Vet al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007; 18: 1057-1071
3. Rossing K, Mischak H, Rossing P et al. The urinary proteome in diabetes and diabetes-associated complications: new ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008; 2: 997-1007
4. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1: 874-884
5. Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 458-461
6. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31: 462-465
7. Buyse M, Sargent DJ, Grothey A et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7: 309-317
8. Otu HH, Can H, Spentzos D et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diab Care 2007; 30: 638-643
9. Rossing K, Mischak H, Dakna M et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-1290
10. Snell-Bergeon JK, Maahs DM, Ogden LG et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diab Technol Ther 2009; 11: 1-9
11. Jantos-Siwy J, Schiffer E, Brand K et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009; 8: 268-281
12. Merchant ML, Perkins BA, Boratyn GM et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20: 2065-2074
13. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402
14. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
15. Haller H, Viberti GC, Mimran A et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403-408
16. Rossing K, Mischak H, Parving HH et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005; 68: 193-205
17. Molina F, Dehmer M, Perco P et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant 2010; 25: 1015-1018
18. Dominiczak AF, Herget-Rosenthal S, Delles C et al. Systems biology to battle vascular disease. Nephrol Dial Transplant 2010; 25: 1019-1022
19. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009; 12: 80-87
20. Cressey D. Health economics: life in the balance. Nature 2009; 461: 336-339
21. Delea TE, Sofrygin O, Palmer JL et al. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J Am Soc Nephrol 2009; 20: 2205-2213